Novel therapeutic molecular targets for amyloid-beta pathology in Alzheimer's disease

阿尔茨海默病β淀粉样蛋白病理学的新治疗分子靶点

• 批准号: 380058
• 负责人: Takahashi Hideto
• 金额: $ 63.53万
• 依托单位: Institut de recherches cliniques de Montral
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2018
• 资助国家: 加拿大
• 起止时间: 2018-03-01 至 2023-03-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=380058&lang=en
• 关键词: Alzheimer'S Disease; Amyloid-Beta Pathology; Cell Adhesion; Molecular And Cellular Neuroscience; Neurobiology; Synapse Biology

Alzheimer's disease is the most common form of dementia in the elderly. As the world's population ages, many advanced countries including Canada face a growing burden of care for patients with Alzheimer's disease. Loss of brain cell connections called syn

阿尔茨海默病是老年人中最常见的痴呆症。随着世界人口老龄化，包括加拿大在内的许多发达国家都面临着照顾阿尔茨海默病患者的日益沉重的负担。大脑细胞连接syn丢失